CANTON, Mass.–(BUSINESS WIRE)–Abveris, Inc., a leader in contract research antibody discovery, today
announced the deployment of the Berkeley Lights, Inc. Beacon®
optofluidic platform for antibody discovery.
Concurrent with this announcement, Abveris will be launching a sister
company, AbX Biologics, with an exclusive focus on therapeutic antibody
discovery services. AbX Biologics will partner with biopharma companies
to provide premium contract research capitalizing on a combination of
proprietary in vivo technologies and the Beacon platform. The full AbX
Biologics solution is expected to launch in 2020, with beta
collaborations beginning Q3 2019. Abveris will continue to provide
critical reagent antibody discovery and other antibody-related services.
“We are committed to integrating new and innovative technologies to our
expanding suite of antibody discovery capabilities in an effort to
continue providing premium services for our partners. We believe that
the pioneering technology of the Beacon platform in combination with our
own cutting-edge discovery expertise will enable us to deliver
development-ready candidates in industry-leading timelines,” said Tracey
Mullen, Chief Operating Officer of AbX Biologics and Abveris.
The Beacon platform provides accelerated single-cell screening and
high-resolution analysis to identify and isolate antigen-specific
antibody-secreting cells in a single day. AbX Biologics will leverage
this groundbreaking technology in combination with its proprietary
immunization and high-throughput characterization capabilities to
provide a streamlined, best-in-class therapeutic antibody discovery
offering to its growing customer base.
“We are delighted that Abveris and AbX Biologics have selected the
Beacon Platform and our Antibody Discovery workflow for their
therapeutic antibody discovery programs,” said Dr. Eric Hobbs, CEO of
Berkeley Lights. “Berkeley Lights is driven to help companies accelerate
the discovery of the best cells for their unique programs. We believe
our work with AbX Biologics will help speed its antibody discovery
efforts by screening more potential drug candidates faster, reducing the
time from target to high value lead, and ultimately delivering new
therapies to market faster.”
About Abveris: Abveris is a premium Boston-area contract research
organization specializing in antibody discovery. Abveris partners with
large and small biopharmaceutical companies to discover novel
therapeutic products and critical reagent antibodies using diverse
platforms, including the proprietary DiversimAb™ hyperimmune mouse
technology and a variety of humanized mice. Additional information about
Abveris is available at www.abveris.com
About Berkeley Lights: Berkeley Lights, Inc. (BLI) is a digital
cell biology company that develops and commercializes workflows and
processes for the biotechnology sector to accelerate
the design, discovery, development, and delivery of cell-based
products. By operating at the intersection of biology, technology and
information, our workflows automate the manipulation, analysis and
selection of individual cells, creating ultimate scalability and deep
cell insights. BLI enables the rapid deployment of biology for the
production of sustainable and scalable sources of food, therapies, and
energy.
The Beacon platform is for Research Use Only. Not for use in diagnostic
procedures.
Contacts
Garren Hilow
contact@abverisantibody.com
781-562-1170